APA (7th ed.) Citation

T, C., E, B., C, S., A, S., L, A., P, H., . . . P, M. (2022). No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. Disease markers, 2022, 3132941. https://doi.org/10.1155/2022/3132941

Chicago Style (17th ed.) Citation

T, Castaño-Bonilla, et al. "No Evidence That CD33 Rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group." Disease Markers 2022 (2022): 3132941. https://doi.org/10.1155/2022/3132941.

MLA (9th ed.) Citation

T, Castaño-Bonilla, et al. "No Evidence That CD33 Rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group." Disease Markers, vol. 2022, 2022, p. 3132941, https://doi.org/10.1155/2022/3132941.